1型糖尿病妊娠中胰岛素泵与每日多次注射比较:CONCEPTT随机试验预设分析
该预设分析纳入CONCEPTT试验中248名1型糖尿病孕妇,比较胰岛素泵与每日多次注射(MDI)对血糖控制、生活质量和妊娠结局的影响。结果显示MDI组HbA1c降幅更大、达标率更高,且妊娠期高血压、新生儿低血糖和NICU入住率更低;泵组低血糖焦虑改善更明显但健康幸福感下降更多。提示妊娠期胰岛素泵治疗的实施可能欠佳。
要点
- MDI组从随机到34周的HbA1c降幅大于泵组(-0.55±0.59 vs -0.32±0.65%,P=0.001)。
- 泵组妊娠期高血压(14.4 vs 5.2%,P=0.025)、新生儿低血糖(31.8 vs 19.1%,P=0.05)和NICU入住>24h(44.5 vs 29.6%,P=0.02)更多。
- 泵组低血糖相关焦虑改善更大(P=0.05),但健康/幸福感下降更明显(P=0.02)。
核心结论
- 在CONCEPTT试验中,MDI使用者比泵使用者更可能获得更好的血糖结局,且妊娠期高血压、新生儿低血糖和NICU入住更少。
- 数据提示妊娠期胰岛素泵治疗的实施可能欠佳。
研究设计与样本
- CONCEPTT试验的预设分析,纳入31个中心的248名1型糖尿病孕妇,随机化按泵与MDI及HbA1c分层。
- 主要结局为随机化至妊娠34周HbA1c变化,关键次要结局包括CGM指标、母婴健康和患者报告结局。
主要发现
- 基线时泵使用者更常有稳定伴侣(P=0.003)、更可能孕前服用维生素(P=0.03)、更少吸烟(P=0.02)。
- 孕早期血糖相当:HbA1c 6.84±0.71 vs 6.95±0.58%(51±7.8 vs 52±6.3 mmol/mol,P=0.31),CGM目标时间51±14 vs 50±13%(P=0.40)。
- 34周时MDI组HbA1c降幅更大(-0.55±0.59 vs -0.32±0.65%,P=0.001);24周和34周MDI组更可能达到目标HbA1c(P=0.009和P=0.001)。
- 泵组高血压疾病更多(P=0.011),主要由妊娠期高血压增加驱动(14.4 vs 5.2%,P=0.025);新生儿低血糖(31.8 vs 19.1%,P=0.05)和NICU入住>24h(44.5 vs 29.6%,P=0.02)更多。
- 泵组低血糖相关焦虑改善更大(P=0.05),但健康/幸福感下降更明显(P=0.02)。
关键数值与推荐
- 孕早期HbA1c目标值未在原文中明确报告,但基线值泵组6.84±0.71%、MDI组6.95±0.58%。
- 34周HbA1c变化泵组-0.32±0.65%、MDI组-0.55±0.59%(P=0.001)。
- 妊娠期高血压发生率泵组14.4%、MDI组5.2%(P=0.025)。
- 新生儿低血糖发生率泵组31.8%、MDI组19.1%(P=0.05);NICU入住>24h泵组44.5%、MDI组29.6%(P=0.02)。
临床怎么用
- 对于1型糖尿病孕妇,MDI可能较胰岛素泵更易实现更好的血糖控制和更低的母婴不良结局风险。
- 使用胰岛素泵的孕妇需关注妊娠期高血压、新生儿低血糖和NICU入住风险,并优化泵治疗实施。
- 泵治疗可能改善低血糖焦虑但需监测健康幸福感下降。
局限性
- 为预设分析而非主要终点,可能存在混杂因素(如基线社会人口学差异)。
- 泵与MDI分组非随机分配,尽管随机化按泵与MDI分层。
- 原文未报告泵治疗实施细节(如泵类型、设置调整)及依从性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare glycemic control, quality of life, and pregnancy outcomes of women using insulin pumps and multiple daily injection therapy (MDI) during the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). RESEARCH DESIGN AND METHODS: This was a prespecified analysis of CONCEPTT involving 248 pregnant women from 31 centers. Randomization was stratified for pump versus MDI and HbA1c. The primary outcome was change in HbA1c from randomization to 34 weeks' gestation. Key secondary outcomes were continuous glucose monitoring (CGM) measures, maternal-infant health, and patient-reported outcomes. RESULTS: At baseline, pump users were more often in stable relationships (P = 0.003), more likely to take preconception vitamins (P = 0.03), and less likely to smoke (P = 0.02). Pump and MDI users had comparable first-trimester glycemia: HbA1c 6.84 ± 0.71 vs. 6.95 ± 0.58% (51 ± 7.8 vs. 52 ± 6.3 mmol/mol) (P = 0.31) and CGM time in target (51 ± 14 vs. 50 ± 13%) (P = 0.40). At 34 weeks, MDI users had a greater decrease in HbA1c (-0.55 ± 0.59 vs. -0.32 ± 0.65%, P = 0.001). At 24 and 34 weeks, MDI users were more likely to achieve target HbA1c (P = 0.009 and P = 0.001, respectively). Pump users had more hypertensive disorders (P = 0.011), mainly driven by increased gestational hypertension (14.4 vs. 5.2%; P = 0.025), and more neonatal hypoglycemia (31.8 vs. 19.1%, P = 0.05) and neonatal intensive care unit (NICU) admissions >24 h (44.5 vs. 29.6%; P = 0.02). Pump users had a larger reduction in hypoglycemia-related anxiety (P = 0.05) but greater decline in health/well-being (P = 0.02). CONCLUSIONS: In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy.
引用
- Feig DS, Corcoy R, Donovan LE, et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care. 2018. PMID: 30327362. doi:10.2337/dc18-1437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。